MALAT1 and cancer: As shown in Table 2, the subgroup analysis for cancer type suggested that MALAT-1 up-regulation was a strong prognostic biomarker in both patients with TNBC (HR = 1.88, 95% CI = 1.45‒2.44, P<0.0001) and in those with mixed type breast cancer (HR = 2.57, 95% CI = 1.71‒3.85, P<0.0001).